Navigation Links
Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
Date:5/8/2013

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "should," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding:  the Special Protocol Assessment, or SPA, and the protocol for the Contrave® cardiovascular outcomes trial, or Light Study; the potential for, and timing of, the accrual and adjudication of MACE; the expected retention rate for patients in the Light Study; the probability of success of the Light Study; the potential for, and timing of, resubmission and approval of a NDA for Contrave based on interim results of the Light Study; the possibility of resubmitting the Contrave NDA with the independent DMC report on the interim analysis and without the clinical study report for the interim analysis; the potential to accelerate the timing of the review of the Contrave NDA; the safety and effectiveness of Contrave; the potential for past Contrave clinical trials to predict the outcome of future Contrave clinical trials; the potential to enter into a collaborative partnership to fund Phase III development and, if approved, commercialization of Empatic™; the potential for the FDA to approve an NDA for Empatic without requiring data from a cardiovascular outcomes trial in addition to the data obtained from the Light Study; and the use of pharmacotherapy to treat obesity. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ materially from those expressed or implied in this release due to the risk and uncertainties inherent in the Orex
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Orexigen Therapeutics to Present at Upcoming Conferences
2. Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors
3. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
4. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
5. Nile Therapeutics Reports 2011 Third Quarter Financial Results
6. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
7. Fate Therapeutics Strengthens Its iPSC Platform
8. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
9. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
10. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
11. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 1, 2014  Discovery Laboratories, Inc. (Nasdaq: DSCO) ... a Phase II Small Business Innovation Research Grant ... the National Institute of Allergy and Infectious Diseases ... to support the development of the Company,s aerosolized ... to mitigate acute and chronic/late-phase radiation-induced lung injury. ...
(Date:10/1/2014)... 2014 As the world takes its first ... doubt that this century would mark the beginning of a ... medicine science. The fact that the world is experiencing a ... the scientific community. Almost half of these chronic conditions are ... prevented with medical care and intervention. While the world is ...
(Date:10/1/2014)... Award winning unified communications (UC) and ... collaboration bundles that combine next generation communication technologies. ... for low, flat rate fees. With four ... optimized solutions to meet their technology needs. , ... minutes (1K, 5K, 10K increments) or audio minutes ...
(Date:10/1/2014)... -- Industry leaders from retail pharmacies ... the theme, ,Commercial Opportunities in the Era of Reform, ... Elsevier , a world-leading provider of scientific, technical ... gathering of some of the industry,s most prominent healthcare ... and in the future. The Elsevier Healthcare ...
Breaking Biology Technology:Discovery Labs Receives SBIR Grant Valued up to $3.0 Million to Support Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives SBIR Grant Valued up to $3.0 Million to Support Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3Fighting Mortality and Morbidity of Chronic Health Disorders during Open Access Week 2Fighting Mortality and Morbidity of Chronic Health Disorders during Open Access Week 3SoundConnect Launches New Audio, Web and Video Bundles 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3
... Idenix,Pharmaceuticals, Inc. (Nasdaq: IDIX ), a biopharmaceutical ... the treatment of human viral,and other infectious diseases, announced ... the 43rd Annual Meeting of the European,Association for the ... Milan, Italy,April 23 - 27, 2008. Full abstracts can ...
... Guaranteed Purchase Minimums - Carrington Provides Product Development, Manufacturing ... ... Distribution, IRVING, Texas, Feb. 25 Carrington,Laboratories, Inc. ... agreement with Universal Harvest Corporation of Nevada. Under the,terms of ...
... N.J., Feb. 25 Barr Pharmaceuticals,Inc. (NYSE: ... subsidiary, Duramed,Pharmaceuticals, Inc., has received notification that ... accepted for review its New Drug Application,(NDA) ... mg and ethinyl estradiol tablets 0.01 mg) ...
Cached Biology Technology:Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL) 2Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL) 3Carrington and Universal Harvest Sign Supply Agreement 2Duramed's Lo SEASONIQUE(R) NDA Accepted for Filing by FDA 2Duramed's Lo SEASONIQUE(R) NDA Accepted for Filing by FDA 3Duramed's Lo SEASONIQUE(R) NDA Accepted for Filing by FDA 4
(Date:9/30/2014)... Evidence of the environmental effects of moorland burning is ... the subject, with the aim of relieving tensions on ... , The EMBER (Effects of Moorland Burning on the ... burning on moorland, which is practised predominantly to support ... impacts on peat hydrology, peat chemistry and physical properties, ...
(Date:9/30/2014)... nature as something that we enjoy when we visit a ... we think of ourselves as a part of nature? A ... a house? , The answers to these questions reflect ... our speech and in cultural artifacts. , A new Northwestern ... American Indian Center of Chicago and the Menominee tribe of ...
(Date:9/30/2014)... all have in common? Unlike most eukaryotic multicellular ... diploid, these organisms are all polyploid, meaning they have ... have 3 and 4 sets of chromosomes, respectively, and ... in fact most plant species are polyploid. Polyploidy, or ... but only recently, with the development of molecular tools, ...
Breaking Biology News(10 mins):Grouse moor burning causes widespread environmental changes 2The cultural side of science communication 2Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 2Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 3Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 4
... have known for nearly 90 years that cancer ... significance of this phenomenon is not completely understood. ... issue of Cancer Cell reveals a functional connection ... the results suggest that inhibition of a specific ...
... Researchers from the Pacific Northwest Research Institute (PNRI) and ... uncovered a pattern of DNA damage in connective tissues ... the early stages of breast cancer and possibly serve ... cancer. , In the United States, breast cancer is ...
... groundbreaking new study in the June issue of American ... California, Santa Barbara) and Michael J. Donoghue (Yale University) ... succulent cactus. , "The cactus form is often heralded ... form and function in plants," write the authors. "A ...
Cached Biology News:Researchers attack tumor cells by exploiting dependency on sugar metabolism 2Links between DNA damage and breast cancer studied 2
Nuclear/Cytosol Fractionation Kit Research Focus: other Storage Temperature: 4C Shipping Temperature: 4C...
Peptide-affinity Purified Polyclonal Antibody to MTR...
Polyclonal Antibody to AGAP1 / Centaurin, gamma 2...
Polyclonal Antibody to PRG3...
Biology Products: